LOS ANGELES LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (NASDAQ: FOLD). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased or otherwise acquired Amicus shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On October 2, 2015, Amicus announced that after meeting with FDA officials, the Company does not anticipate being able to submit a new drug application (NDA) for migalastat, the company's Fabry disease treatment, by the end of the year. When the truth was revealed, shares dropped harming investors.
If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.